We are not in production yet in NSW (McPhillamys), Duketon (WA) is humming like a well oiled machine according to the annual report in Dec and there are no fires there.
RRL's underperformance is due to its growth perception. RRL has an MO of growing organically while our peers (NST, EVN and SAR) have the perception of effectively applying M&A... For that MO, RRL will always have a niche in my portfolio. She is safe albeit a little too safe for some investors. I cannot fault Duketon operationally nor do I disagree that growing organically is a good approach. So far over the years the BOD have deployed earnings where it counts for early investors like me and that is on dividends. Building McPhillamys will take time but is a much safer approach in my opinion than M&A which a fraught with risk when the gold price is this high. But make no mistake RRL will pick up assets when the price is right and she will catch the Goldphoria when it matters.
- Forums
- ASX - By Stock
- RRL
- Open letter to RRL Board & Management
RRL
regis resources limited
Add to My Watchlist
2.23%
!
$4.39

Open letter to RRL Board & Management, page-70
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.39 |
Change
-0.100(2.23%) |
Mkt cap ! $3.316B |
Open | High | Low | Value | Volume |
$4.47 | $4.53 | $4.37 | $16.81M | 3.793M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 51252 | $4.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.39 | 7201 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 51252 | 4.360 |
4 | 37004 | 4.350 |
2 | 24411 | 4.340 |
2 | 6157 | 4.310 |
5 | 37325 | 4.300 |
Price($) | Vol. | No. |
---|---|---|
4.390 | 7201 | 1 |
4.400 | 28087 | 1 |
4.410 | 38340 | 4 |
4.420 | 26563 | 3 |
4.430 | 15681 | 1 |
Last trade - 16.17pm 27/06/2025 (20 minute delay) ? |
Featured News
RRL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online